These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37148782)

  • 1. Amyloidosis and the Kidney: An Update.
    Nader R; Angel-Korman A; Havasi A
    Semin Nephrol; 2022 Nov; 42(6):151343. PubMed ID: 37148782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney Transplantation in Systemic Amyloidosis.
    Angel-Korman A; Havasi A
    Transplantation; 2020 Oct; 104(10):2035-2047. PubMed ID: 32053574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal transplantation in amyloidosis and MIDD.
    Stern L; Havasi A
    Front Biosci (Elite Ed); 2015 Jan; 7(1):149-57. PubMed ID: 25553370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report.
    Al-Zoairy R; Viveiros A; Zoller H; Schneeberger S; Oberhuber G; Gunsilius E; Tilg H; Wolf D; Rudzki JD
    J Med Case Rep; 2020 Oct; 14(1):201. PubMed ID: 33099313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Amyloidosis and Kidney Transplantation: An Update.
    Anand SK; Sanchorawala V; Verma A
    Semin Nephrol; 2024 Jan; 44(1):151496. PubMed ID: 38490903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation.
    Fenoglio R; Baldovino S; Ferro M; Sciascia S; Rabajoli G; Quattrocchio G; Beltrame G; Naretto C; Rossi D; Alpa M; Barreca A; Papotti MG; Roccatello D
    J Nephrol; 2021 Feb; 34(1):231-240. PubMed ID: 32472525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Amyloidosis: Presentation, Diagnosis, and Management.
    Gurung R; Li T
    Am J Med; 2022 Apr; 135 Suppl 1():S38-S43. PubMed ID: 35085515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and outcomes of renal amyloidosis in Hong Kong.
    Lin RCC; Yuen SK; Cheung SF; Tang HL; Fung SKS
    Nephrology (Carlton); 2022 Nov; 27(11):869-876. PubMed ID: 36054582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I Approach Light Chain Amyloidosis.
    Chowdhury RB; Leung N
    G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney and liver involvement in monoclonal light chain disorders.
    Pozzi C; Locatelli F
    Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
    Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
    Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal amyloidosis].
    Kościelska M; Shebani Z; Matuszkiewicz-Rowińska J
    Przegl Lek; 2013; 70(4):205-10. PubMed ID: 23991559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo AL amyloidosis in the kidney allograft.
    Qian Q; Nasr SH; Fidler ME; Cornell LD; Sethi S
    Am J Transplant; 2011 Mar; 11(3):606-12. PubMed ID: 21342449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and treatment of AL amyloidosis.
    Sezer O; Eucker J; Jakob C; Possinger K
    Clin Nephrol; 2000 Jun; 53(6):417-23. PubMed ID: 10879660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
    Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
    Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
    Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
    Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.